Farber's first description of the use of folate antagonists in the management of acute lymphoblastic leukaemia (ALL),' emphasised the limitations of treatment because of intestinal toxicity such as gastrointestinal ulceration and haemorrhage.2 Although such severe side effects are now less common they remain an important potential hazard. Xylose malabsorption has been reported in association with methotrexate (MTX) treatment in children with ALL3 and it has been suggested that the absorption of the drug itself may be similarly impaired.45 This may contribute to the wide variations in serum MTX concentrations after a standard oral dose.4 6 7 Some children achieve only very low concentrations, therefore, which may be associated with a suboptimal response to treatment.
As part of a detailed study of factors influencing MTX absorption, jejunal biopsies were carried out in association with routine bone marrow aspiration. This paper describes striking abnormalities in the jejunal mucosal cells both on light and electron microscopy.
Accepted for publication 19 November 1980 Patients and methods Twenty jejunal biopsy specimens were studied; 10 were from children with ALL receiving MTX treatment whose ages ranged from 2-6 to 12-5 yr and 10 were from sequential patients being investigated for diarrhoea or In each region, the number of villi having greater than 50% damaged enterocytes was counted and expressed as a percentage of the total number of suitably orientated villi.
Ultrathin sections (50-100 nm) were cut from selected areas using an LKB Ultra-tome 111. These were lifted off copper grids and double-stained with uranyl acetate followed by lead citrate. The sections were then examined with an AEI EM 801 transmission electron microscope.
Results
The majority of biopsy specimens from children receiving MTX treatment showed no distinct abnormalities with H and E staining. The semithin sections stained with toluidine blue showed greater cellular detail and revealed several alterations not seen with H and E (Fig. 1) . These abnormalities were most striking in those patients who had received MTX between 24 and 72 h before biopsy (group A).
On light microscopy cellular atrophy was evident in the upper and middle regions of villi with marked enlargement of the lateral basal intercellular spaces (LBIS) (Fig. 1) . Many cells showed vacuolar degeneration associated with reduced staining affinity. In two cases areas of villus epithelium were separated from the basement membrane to produce small blebs. The nature of cellular abnormalities varied widely both between patients and within individual villi. In some, distention of the LBIS was the dominant abnormality, whereas in others cellular degeneration and vacuolation were prominent.
Semi-quantitative assessment of the biopsy specimens indicated a relation between the severity of the lesions and the time since MTX treatment, up to 72 h before biopsy (Fig. 2) . Similarly, but to a lesser extent, there was an association with the total dose of MTX given before biopsy. In group A biopsies, the enterocytes in the upper part of the villi (Table) . There was a similar difference in the middle region but damage to enterocytes in the lower region of the villi was evident only in the specimens of group A patients Overall, there was a significantly higher percentage of damaged villi in group A than in group B biopsy specimens (p < 0 01). Nine of the control specimens showed normal villus architecture with AL both H and E and toluidine blue stains. A specimen from one patient showed the abnormalities characteristic of coeliac disease and has therefore been excluded from further reference. There was no significant difference between the SVR of specimens * of MTX-treated children (groups A and B) and the nine controls.
On electron microscopy the most marked changes were again seen in the specimens of children who had received MTX 24 to 72 h previously. Ultrastructural abnormalities involved the microvilli, cell membranes, and cytoplasmic organelles. The electron micrographs shown are of abnormalities present in cells in the middle regions of villi. In damaged enterocytes the microvilli were uneven, shortened and loosely packed (Fig. 3) . In some cells, more marked changes were apparent with loss of staining properties, vacuolation and atrophy.
There was marked enlargement of the LBIS, which were wedge-shaped, the apex being at the mucosal surface and the base toward the basement membrane. These spaces were traversed at various points by delicate strands of cytoplasm extending from neighbouring cells and meeting at a desmosome.
Most enterocytes remained in contact with the basement membrane, which was itself preserved (Fig. 4) . Intercellular contact was also maintained along the basement membrane in most areas, although in some there was complete separation of cells.
There was a marked reduction in the hyaloplasmic bulk with relative crowding of organelles, particularly mitochondria. In some cells focal dilatation of endoplasmic reticulum and Golgi apparatus was noted and the resulting cystic spaces gave rise to a degenerative vacuolar appearance (Fig. 5) . In some villi single enterocytes or clusters of two or three cells were necrotic with swollen electrondense mitochondria and little internal structure discernible (Fig. 5) . Apart from some degree of elongation, the nuclear structure was generally preserved, except in necrotic cells, where nuclei were pyknotic and electron-dense.
In contrast, the villi of patients in group B, who had received a single dose of MTX generally showed less marked changes which when present were patchy in their distribution. Microvilli were more regular and 
Discussion
In interpreting histological abnormalities present in the small bowel of children with ALL, it should be borne in mind that various factors, other than MTX treatment, have been reported to be associated with villus damage. For example, villus shortening has been noted in a number of extraintestinal malignancies,11 although in a necropsy study of children with ALL, villus atrophy was not a feature.'2 Moreover, it is unlikely that leukaemiaper se was the causal factor as all our patients were in remission and in some (group B) jejunal histology was quite normal. Folate deficiency which may alter villus structure'3 was not present, nor had other cytotoxic drugs (which might cause damage) been given to any of our patients for at least one week before biopsy. The contention that MTX alone was responsible is further supported by the relation between drug administration and, to a lesser extent, its total dose, and the degree of morphological damage ( A predominant feature in MTX-treated patients with ALL was the markedly enlarged LBIS with enterocyte atrophy. A similar morphological change has been reported in animals during water absorption20 and following in vitro incubation of strips of rat small gut in hypotonic saline.2' Apart from premedication, our patients were not given fluids immediately before biopsy, and although this was common to all those studied, the abnormalities described were present only in group A patients. It may be that these changes are due to a metabolic 794, Small bowel enterocyte abnormalities caused by methotrexate treatment derangement causing an alteration either in intercellular binding or in fluid transport resulting in an accumulation of fluid between the enterocytes.
In this study, two of the three patients given MTX within 3 h of biopsy, showed some degree of structural damage (Table) . This suggests that, in addition to crypt cell generation, there is a direct toxic effect also on mature enterocytes. This may be related to the effect of the drug, in non-dividing cells,22 23 upon RNA and protein synthesis. A very early in vitro effect of MTX on enterocyte oxygen consumption has been described in animal studies. 24 At the other extreme, the relative absence of damage 96 h after a single dose of MTX is consistent with the normal cell turnover time in jejunum. 25 The variation in the degree of damage between cells on the same villus was a striking feature. In places, normal enterocytes were adjacent to markedly atrophic or necrotic cells (Fig. 5) . These variations may be caused by local differences in DNA or RNA, the concentrations of dihydrofolate reductase or concentrations of folic acid intermediary metabolites at the time of MTX administration.
Whatever the pathogenesis of these changes, it would appear that even in the absence of toxic side-effects, therapeutic doses of MTX may cause alterations in villus epithelial architecture which may account for some of the pathophysiological abnormalities already described.3 5
